SCHEMBL736702

SCHEMBL736702

C[C@@H]1C(=O)N(CCCN2CCC3(CC3)[C@H](O)C2)CCN1c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 2/20 0.41
MMP2 P08253 1/20 0.37
MMP14 P50281 1/20 0.37
OPRM1 P35372 6/20 0.37
HTR1A P08908 5/20 0.37
DRD2 P14416 5/20 0.37
DRD4 P21917 5/20 0.37
HRH2 P25021 5/20 0.37
HTR1D P28221 5/20 0.37
HTR2A P28223 5/20 0.37
HTR2C P28335 5/20 0.37
HTR7 P34969 5/20 0.37
OPRK1 P41145 5/20 0.37
DRD1 P21728 4/20 0.37
DRD5 P21918 4/20 0.37
SLC6A2 P23975 4/20 0.37
SLC6A4 P31645 4/20 0.37
DRD3 P35462 4/20 0.37
OPRD1 P41143 4/20 0.37
HTR2B P41595 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735228 1.00 ADAMTS5 (0.41) ADAMTS5MMP2MMP14OPRM1HTR1A
SCHEMBL734859 1.00 ADAMTS5 (0.41) ADAMTS5MMP2MMP14OPRM1HTR1A
SCHEMBL734858 1.00 ADAMTS5 (0.41) ADAMTS5MMP2MMP14OPRM1HTR1A
SCHEMBL736584 0.93 NOTUM (0.36) ADAMTS5MMP2MMP14OPRM1HTR1A
SCHEMBL736585 0.93 NOTUM (0.36) ADAMTS5MMP2MMP14OPRM1HTR1A
SCHEMBL735558 0.91 AR (0.37) ADAMTS5P2RX7NOTUM
SCHEMBL733467 0.91 AR (0.37) ADAMTS5P2RX7NOTUM
SCHEMBL733466 0.91 AR (0.37) ADAMTS5P2RX7NOTUM
SCHEMBL733556 0.90 GRM2 (0.32) ADAMTS5OPRM1P2RX7SIGMAR1
SCHEMBL733555 0.90 GRM2 (0.32) ADAMTS5OPRM1P2RX7SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 ADAMTS5 4707/4885MMP2 3027/4885MMP14 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.